Table 1.
General characteristics, type of cancer and ICI molecules.
| Characteristic | n/19 (%) (Median IQR) |
|---|---|
| Gender (Male) | 16 (84.2) |
| Age, years | 73 (67–76) |
| Mean time from ICI initiation and irAE onset, months | 4 (2–10) |
| Type of cancer | |
| Melanoma | 5 (26.3) |
| Lung | 3 (15.8) |
| Liver | 3 (15.8) |
| Urothelial | 3 (15.8) |
| Prostate | 2 (10.5) |
| Acute leukemia | 2 (10.5) |
| Myelodysplastic syndrome | 1 (5.3) |
| Previous rheumatic diseases | |
| Chondrocalcinosis | 2 (10.5) |
| HLA-B27 associated uveitis | 1 (5.3) |
| Psoriasis | 1 (5.3) |
| Fibromyalgia | 1 (5.3) |
| Osteoarthritis | 1 (5.3) |
| Type of Checkpoint inhibitors | |
| Monotherapy | |
| Pembrolizumab | 6 (31.6) |
| Anti TIM3 | 3 (15.8) |
| Nivolumab | 3 (15.8) |
| Atezolizumab | 2 (10.5) |
| Durvalumab | 1 (5.3) |
| Combined therapy | |
| Pembrolizumab + Epacadostat | 1 (5.3) |
| Atezolizumab + Cabozantinib | 1 (5.3) |
| Nivolumab + Rigorafenib | 1 (5.3) |
| Ipilimumab + Nivolumab | 1 (5.3) |
Anti-TIM3: Anti T cell immunoglobulin mucin domain 3; IQR: Interquartile Range.